AQR Capital Management
ABUS icon

AQR Capital Management’s Arbutus Biopharma ABUS Stock Holding History

AQR Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Buy
31,741
+7,922
+33% +$34.8K ﹤0.01% 3830
2026
Q1 		$107K Buy
23,819
+7,036
+42% +$30.8K ﹤0.01% 3679
2025
Q4 		$80.7K Buy
16,783
+1,550
+10% +$6.97K ﹤0.01% 3475
2025
Q3 		$69.2K Sell
15,233
-22,469
-60% -$82.5K ﹤0.01% 3400
2025
Q2 		$116K Sell
37,702
-10,468
-22% -$34.8K ﹤0.01% 3151
2025
Q1 		$168K Sell
48,170
-554
-1% -$1.85K ﹤0.01% 2923
2024
Q4 		$159K Buy
48,724
+15,006
+45% +$55.2K ﹤0.01% 2709
2024
Q3 		$130K Buy
+33,718
New +$129K ﹤0.01% 2627
2023
Q4 		– Sell
-40,598
Closed -$82.4K – 2322
2023
Q3 		$82.4K Buy
40,598
+26,075
+180% +$54.7K ﹤0.01% 2249
2023
Q2 		$33.4K Sell
14,523
-6,412
-31% -$16.7K ﹤0.01% 2170
2023
Q1 		$63.4K Sell
20,935
-1,818
-8% -$5.13K ﹤0.01% 2134
2022
Q4 		$53K Sell
22,753
-69
-0.3% -$165 ﹤0.01% 2168
2022
Q3 		$44K Buy
22,822
+3,392
+17% +$7.99K ﹤0.01% 2152
2022
Q2 		$53K Buy
+19,430
New +$49.7K ﹤0.01% 2131
2021
Q3 		– Sell
-19,036
Closed -$58K – 2236
2021
Q2 		$58K Buy
+19,036
New +$59K ﹤0.01% 2207
2019
Q2 		– Sell
-28,128
Closed -$101K – 2057
2019
Q1 		$101K Sell
28,128
-93,514
-77% -$359K ﹤0.01% 2135
2018
Q4 		$466K Buy
121,642
+75,066
+161% +$370K ﹤0.01% 1808
2018
Q3 		$440K Buy
46,576
+27,354
+142% +$272K ﹤0.01% 1991
2018
Q2 		$140K Buy
+19,222
New +$114K ﹤0.01% 2267

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management's ABUS Position: Q2 2026 in Review

AQR Capital Management increased its Arbutus Biopharma (ABUS) stake by 33% in Q2 2026, buying an estimated $34.8K and bringing the position to 31,741 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

AQR Capital Management first reported a position in ABUS in Q2 2018 and has held it in 19 quarters since. The position peaked at $466K in Q4 2018. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • AQR Capital Management held 31,741 shares of Arbutus Biopharma worth $152K as of Q2 2026.
  • AQR Capital Management bought 7,922 Arbutus Biopharma shares in Q2 2026, an estimated $34.8K.
  • Arbutus Biopharma made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3830 holding.
  • AQR Capital Management first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 19 quarters since.
  • AQR Capital Management's Arbutus Biopharma position peaked at $466K in Q4 2018.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.